Applied DNA Sciences (APDN)
(Delayed Data from NSDQ)
$0.41 USD
-0.02 (-4.21%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $0.42 +0.01 (2.44%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
APDN 0.41 -0.02(-4.21%)
Will APDN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for APDN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APDN
Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year?
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
APDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADT (ADT) Q2 Earnings and Revenues Miss Estimates
Proto Labs (PRLB) Q2 Earnings and Revenues Top Estimates
Kennametal (KMT) Q4 Earnings and Revenues Miss Estimates
Other News for APDN
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Applied DNA Sciences enters manufacturing agreement with Alphazyme
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress